ESR1 testing with digital PCR: A powerful tool for precision oncology
Estrogen receptor–positive (ER+) breast cancer accounts for the majority of breast cancer diagnoses worldwide. While endocrine therapies such as aromatase inhibitors and selective estrogen receptor degraders (SERDs) can be highly effective, treatment resistance frequently develops. One of the best-studied molecular mechanisms of this resistance is mutation of the ESR1 gene, and sensitive detection of these mutations has become a critical part of precision oncology.
